GlassScriptPhysician profile
Kristen Lee
NPI 1942442884
$12,558.93
in general payments reported to CMS, 2019-2025
38 companies · $3,870 in 2025
The $3,870 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $751 · 2021: $1,050 · 2022: $2,063 · 2023: $1,821 · 2024: $2,763 · 2025: $3,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,454.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,317.34 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,169.92 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,229.57 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $706.75 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $680.02 | 2022-2025 | Sucraid, Sucraid |
| Shockwave Medical, INC | $665.57 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $495.25 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $463.67 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $277.71 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.91 | 2019-2023 | Cyltezo |
| Genzyme Corporation | $208.69 | 2023-2024 | |
| Celltrion USA INC. | $185.61 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $181.08 | 2020-2025 | Suflave, Sutab |
| Lilly USA, LLC | $176.61 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $160.66 | 2023-2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $130.21 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $129.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Kerecis Limited | $125.22 | 2021 | |
| Redhill Biopharma INC. | $122.60 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Abbott Laboratories | $121.82 | 2024 | Jeti Peripheral Catheter |
| Ironwood Pharmaceuticals, INC | $112.22 | 2021-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $106.40 | 2022 | |
| Boston Scientific Corporation | $97.43 | 2024 | Angiojet Ultra 5000a |
| Gilead Sciences, INC. | $60.84 | 2022-2025 | |
| Viiv Healthcare Company | $60.78 | 2022-2023 | Apretude |
| Ipsen Biopharmaceuticals, INC | $60.46 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $44.07 | 2025 | Zenpep |
| Phadia US INC. | $37.32 | 2021 | |
| Amgen INC. | $33.82 | 2020 | |
| Vibrant Gastro, INC. | $24.70 | 2025 | Vibrant Starter Kit |
| Ucb, INC. | $23.17 | 2021 | |
| Daiichi Sankyo INC. | $21.39 | 2020 | |
| Shield Therapeutics INC | $20.86 | 2023 | Accrufer |
| Nestle Healthcare Nutrition INC. | $20.69 | 2021 | |
| Alfasigma USA, INC. | $13.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 | |
| Currax Pharmaceuticals LLC | $12.11 | 2022 | |
| Allergan, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.